Alterations of the miR-126-3p/POU2AF1/Spi-B Axis and JCPyV Reactivation in Multiple Sclerosis Patients Receiving Natalizumab

Alterations of the miR-126-3p/POU2AF1/Spi-B Axis and JCPyV Reactivation in Multiple Sclerosis Patients Receiving Natalizumab

Natalizumab (NTZ) can reactivate human polyomavirus John Cunningham polyomavirus (JCPyV) latent infection and lead to progressive multifocal leukoencephalopathy (PML). NTZ modulates the expression of microRNA-126-3p (miR-126-3p) and its target genes, Spi-B, POU2AF1, and vascular cell adhesion molecu...

Full description

Bibliographic Details
Main Authors:	Roberta Mancuso, Simone Agostini, Ambra Hernis, Domenico Caputo, Daniela Galimberti, Elio Scarpini, Mario Clerici
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-03-01
Series:	Frontiers in Neurology
Subjects:	circulating microRNA (miRNA) natalizumab (Tysabri®) JCPyV multiple sclerosis rehabilitation progressive multifocal leukoencephalopathy (PML)
Online Access:	https://www.frontiersin.org/articles/10.3389/fneur.2022.819911/full

Similar Items

Human Polyomavirus JCPyV and Its Role in Progressive Multifocal Leukoencephalopathy and Oncogenesis
by: Luis Del Valle, et al.
Published: (2019-08-01)

JCPyV miR-J1-5p in Urine of Natalizumab-Treated Multiple Sclerosis Patients
by: Simone Agostini, et al.
Published: (2021-03-01)

Discriminating between JCPyV and BKPyV in Urinary Virome Data Sets
by: Rita Mormando, et al.
Published: (2021-05-01)

JCPyV T-Antigen Activation of the Anti-Apoptotic Survivin Promoter—Its Role in the Development of Progressive Multifocal Leukoencephalopathy
by: Luis Del Valle, et al.
Published: (2020-11-01)

Diagnostic Value of JC Polyomavirus Viruria, Viremia, Serostatus and microRNA Expression in Multiple Sclerosis Patients Undergoing Immunosuppressive Treatment
by: Carla Prezioso, et al.
Published: (2022-01-01)

Human polyomaviruses JCPyV and MCPyV in urothelial cell carcinoma: a single institution experience
by: Faisal Klufah, et al.
Published: (2023-12-01)

Divergent Trends of Anti-JCPyV Serum Reactivity and Neutralizing Activity in Multiple Sclerosis (MS) Patients during Treatment with Natalizumab
by: Roberta Antonia Diotti, et al.
Published: (2016-05-01)

Induction of Brain Tumors by the Archetype Strain of Human Neurotropic JCPyV in a Transgenic Mouse Model
by: Luis Del Valle, et al.
Published: (2021-01-01)

JCPyV VP1 Mutations in Progressive Multifocal Leukoencephalopathy: Altering Tropism or Mediating Immune Evasion?
by: Matthew D. Lauver, et al.
Published: (2020-10-01)

Risk Assessment of Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis Patients during 1 Year of Ocrelizumab Treatment
by: Carla Prezioso, et al.
Published: (2021-08-01)

The MAPK/ERK Pathway and the Role of DUSP1 in JCPyV Infection of Primary Astrocytes
by: Michael P. Wilczek, et al.
Published: (2021-09-01)

Should SVGp12 Be Used for JC Polyomavirus Studies? Comment on Prezioso et al. COS-7 and SVGp12 Cellular Models to Study JCPyV Replication and MicroRNA Expression after Infection with Archetypal and Rearranged-NCCR Viral Strains. <i>Viruses</i> 2022, <i>14</i>, 2070
by: Stian Henriksen, et al.
Published: (2022-12-01)

COS-7 and SVGp12 Cellular Models to Study JCPyV Replication and MicroRNA Expression after Infection with Archetypal and Rearranged-NCCR Viral Strains
by: Carla Prezioso, et al.
Published: (2022-09-01)

Polyomavirus Wakes Up and Chooses Neurovirulence
by: Arrienne B. Butic, et al.
Published: (2023-10-01)

The differential presence of human polyomaviruses, JCPyV and BKPyV, in prostate cancer and benign prostate hypertrophy tissues
by: Chenghuang Shen, et al.
Published: (2021-10-01)

Comprehensive proteomic analysis of JC polyomavirus-infected human astrocytes and their extracellular vesicles
by: Larise Oberholster, et al.
Published: (2023-12-01)

Natalizumab Pharmacokinetics and -Dynamics and Serum Neurofilament in Patients With Multiple Sclerosis
by: Undine Proschmann, et al.
Published: (2021-04-01)

Patient monitoring during treatment with natalizumab (ORP-24)
by: Zohreh Abna
Published: (2023-01-01)

Reply to Henriksen, S.; Rinaldo, C.H. Should SVGp12 Be Used for JC Polyomavirus Studies? Comment on “Prezioso et al. COS-7 and SVGp12 Cellular Models to Study JCPyV Replication and MicroRNA Expression after Infection with Archetypal and Rearranged-NCCR Viral Strains. <i>Viruses</i> 2022, <i>14</i>, 2070”
by: Carla Prezioso, et al.
Published: (2022-12-01)

Co-Detection of EBV and Human Polyomavirus JCPyV in a Case of AIDS-Related Multifocal Primary Central Nervous System Diffuse Large B-Cell Lymphoma
by: Mallory T. Barbier, et al.
Published: (2023-03-01)

Prevalence of JC Polyomavirus in Patients with Neuroinvasive Disease of Unknown Etiology in Croatia
by: Tatjana Vilibic-Cavlek, et al.
Published: (2023-12-01)

Switch to ocrelizumab in MS patients treated with natalizumab in extended interval dosing at high risk of PML: A 96-week follow-up pilot study
by: Pilar Santiago-Setien, et al.
Published: (2023-02-01)

Presymptomatic diagnosis with MRI and adequate treatment ameliorate the outcome after natalizumab-associated progressive multifocal leukoencephalopathy (PML).
by: Hans eLindå, et al.
Published: (2013-02-01)

Sequence analysis of the non-coding control region of John Cunningham virus isolates from patients with multiple sclerosis treated with natalizumab
by: Marina A. Tyumentseva, et al.
Published: (2023-04-01)

Type O blood group associates with higher anti‐JC polyomavirus antibody levels
by: Pia Frenken, et al.
Published: (2021-08-01)

JC virus detection and JC virus-specific immunity in natalizumab-treated Multiple Sclerosis patients
by: Mancuso Roberta, et al.
Published: (2012-12-01)

Traces of JC polyomavirus in papillary thyroid cancer: a comprehensive study in Iran
by: Amir Ali Karimi, et al.
Published: (2022-09-01)

The use of natalizumab for multiple sclerosis
by: Brandstadter R, et al.
Published: (2017-06-01)

Insight into Metabolic 1H-MRS Changes in Natalizumab Induced Progressive Multifocal Leukoencephalopathy Brain Lesions
by: Ruth Schneider, et al.
Published: (2017-09-01)

Is There a (Host) Genetic Predisposition to Progressive Multifocal Leukoencephalopathy?
by: Eli eHatchwell
Published: (2015-05-01)

Anxiety and Perception of Disease Control in Multiple Sclerosis Subjects Treated with Natalizumab
by: Francesco Corallo, et al.
Published: (2023-12-01)

Human polyomaviruses and cancer: an overview
by: José Carlos Mann Prado, et al.
Published: (2018-10-01)

Unusually high incidence of polyomavirus JC infection in the higher grade of colorectal cancer tissues in Taiwan
by: Chuan-Yin Fang, et al.
Published: (2022-07-01)

Intercellular Transmission of Naked Viruses through Extracellular Vesicles: Focus on Polyomaviruses
by: Francois Helle, et al.
Published: (2020-09-01)

Progressive multifocal leukoencephalopathy treated with interleukin-7
by: Karl B. Alstadhaug, et al.
Published: (2020-10-01)

PI3K/AKT/mTOR Signaling Pathway Is Required for JCPyV Infection in Primary Astrocytes
by: Michael P. Wilczek, et al.
Published: (2021-11-01)

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: risk reduction, management and possibilities for subsequent immunoregulation
by: Natalia V. Khachanova, et al.
Published: (2019-12-01)

Real-World Effectiveness of Natalizumab in Korean Patients With Multiple Sclerosis
by: Ki Hoon Kim, et al.
Published: (2021-07-01)

Polyomavirus in Saliva of HIV-infected Children, Brazil
by: Tatiana F. Robaina, et al.
Published: (2013-01-01)

Distribution and genetic diversity of the human polyomaviruses JC and BK in surface water and sewage treatment plant during 2009 in Porto Alegre, Southern Brazil
by: J. Comerlato, et al.